CompletedPhase 3

Treatment of COVID-19 Patients With Anti-interleukin Drugs

Belgium342 participantsStarted 2020-04-03

Plain-language summary

The purpose of this study is to test the safety and effectiveness of individually or simultaneously blocking IL-6 and IL-1 versus standard of care on blood oxygenation and systemic cytokine release syndrome in patients with COVID-19 coronavirus infection and acute hypoxic respiratory failure and systemic cytokine release syndrome

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. serum ferritin concentration \>1000 mcg/L and rising since last 24h
✓. single ferritin above 2000 mcg/L in patients requiring immediate high flow oxygen device or mechanical ventilation
✓. lymphopenia defined as \<800 lymphocytes/microliter) and two of the following extra criteria

What they're measuring

Time to Clinical Improvement

Timeframe: at day 15

Trial details

NCT IDNCT04330638

SponsorUniversity Hospital, Ghent

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2020-12-20

Results submitted2022-09-13

View on ClinicalTrials.gov More COVID-19 trials